Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company
PR Newswire•17/11/2026•19:02 ET
0
Key Highlights
- ➤Adrenyx expects Nasdaq listing in the first half of 2027.
- ➤Adrenyx secured an initial US$5 million convertible note arrangement.
- ➤Convertible notes may reach US$10 million aggregate principal amount.
- ➤Private placement could provide up to US$50 million, including notes funding.
- ➤CRHX-101 IND filing and clinical program initiation are near-term priorities.
Expert Statements
Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed
“We are pleased to see the continued advancement of CRHX-101 through a dedicated corporate structure. The establishment of Adrenyx reflects a focused approach to advancing CRHX-101 and supporting its next stage of development. We look forward to the continued progress of CRHX-101 in addressing the significant unmet medical needs of people living with CAH.”
Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company PR Newswire
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026
Get started
Create a free account to read the full story.
